Novozymes 1H 2022 Roadshow Investor Presentation

Novozymes' first-half 2022 investor roadshow presentation reporting 10% organic sales growth and 26.0% EBIT margin. The company increased full-year organic sales growth guidance to 6-8% driven by double-digit growth across four of five business areas and six product launches. Key initiatives include new agriculture partnerships and a planned divestiture of Albumedix minority stake.